Clinical Trials Logo

Liver Cirrhosis clinical trials

View clinical trials related to Liver Cirrhosis.

Filter by:

NCT ID: NCT04823780 Completed - Liver Cirrhosis Clinical Trials

The Effects of Early Enteral Nutrition on Endoscopic Therapy of Esophagogastric Varices in Liver Cirrhosis

Start date: September 1, 2020
Phase:
Study type: Observational

The purpose of this study was to evaluate the safety of early enteral nutrition on endoscopic therapy of esophagogastric varices in Liver Cirrhosis ,and to assess the impact of different eating times on patients, so as to determine the best time for patients to obtain nutrition after surgery.

NCT ID: NCT04814602 Completed - Cirrhosis, Liver Clinical Trials

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

HIPK
Start date: March 30, 2021
Phase: Early Phase 1
Study type: Interventional

Proglumide is an oral cholecystokinin (CCK) receptor antagonist that has been shown in non-clinical studies to reverse hepatic fibrosis and decrease the incidence of hepatocellular carcinoma (HCC). Because of these potential beneficial properties, proglumide may be useful in decreasing the fibrosis and risk for HCC in those with cirrhosis. Although proglumide is safe in those with normal hepatic function, the pharmacokinetics have not been established in those that are hepatic impaired. The purpose of this study is to analyze proglumide blood levels and excretion in subjects with cirrhosis compared to health controls.

NCT ID: NCT04809870 Completed - Esophageal Cancer Clinical Trials

Esophagectomy in Patients With Liver Cirrhosis

Start date: October 1, 2020
Phase:
Study type: Observational

Retrospective and confounder adjusted comparison of perioperative and longterm outcomes of patients requiring an esophagectomy for esophageal cancer with and without concomitant liver cirrhosis.

NCT ID: NCT04806750 Completed - Cirrhosis Clinical Trials

Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension

Start date: October 17, 2016
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG [hepatic venous pressure gradient] ≥12 mmHg as determined by the central reader assigned to this study). Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID (Bis in die, twice daily), 25 mg BID, or 5 mg BID or matching placebo BID.

NCT ID: NCT04791397 Completed - Metabolic Syndrome Clinical Trials

Evaluation of the Effect of IHHT on Vascular Stiffness and Elasticity of the Liver Tissue in Patients With MS.

Start date: April 10, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to assess the effect of interval hypoxy-hyperoxic training (IHHT) on the arterial stiffness and elasticity of the liver tissue in patients with metabolic syndrome and on other components of the metabolic syndrome, and the possibility of their reversible recovery after training.

NCT ID: NCT04790435 Completed - Cirrhosis, Liver Clinical Trials

Acute-On-Chronic Liver Failure In Cirrhotic Patients

Start date: March 1, 2021
Phase:
Study type: Observational

Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure. Traditionally, cirrhosis has been dichotomised in compensated and decompensated, and the transition to decompensated cirrhosis happens when any of the following hallmarks occurs: presence of ascites, variceal haemorrhage and/ or hepatic encephalopathy (HE) . In Egypt, HCV is the main cause of liver cirrhosis followed by HBV

NCT ID: NCT04789213 Completed - Liver Cirrhosis Clinical Trials

Mortality, Morbidity and Risk Factors of Liver Retransplantation

Start date: March 10, 2021
Phase:
Study type: Observational

This study aims to compare the short and long term outcomes of living donor and deceased donor liver retransplantation. Bearing that in mind, the investigators will retrospectively analyze the files of patients whom underwent a liver retransplantation in Memorial Bahcelievler Hospital Organ Transplantation Center.

NCT ID: NCT04787276 Completed - Liver Cirrhosis Clinical Trials

Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy

Start date: January 10, 2017
Phase: N/A
Study type: Interventional

The purpose of study to assess the short-term efficacy and safety of probiotic E.coli Nissle 1917 strain comparing to lactulose and rifaximin in patients with mild (Stage 1-2) or minimal hepatic encephalopathy

NCT ID: NCT04782050 Completed - Liver Cirrhosis Clinical Trials

Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation

DIACEPA
Start date: September 15, 2021
Phase: N/A
Study type: Interventional

Early screening and monitoring of chronic liver diseases in hepatology practice has become crucial. To achieve this goal, hepatology clinics need simple and available tools at the point-of-care to perform disease severity assessment. The objective of this study is to assess the performance of a new non-invasive ultrasound-based system for the assessment of liver fibrosis and steatosis severity, via ultrasound biomarkers such as tissue stiffness (correlated to fibrosis severity) and ultrasound tissue attenuation (correlated to steatosis extent).

NCT ID: NCT04771104 Completed - Liver Cirrhosis Clinical Trials

The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver Cirrhosis

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Sleep disturbances are common among patients with liver cirrhosis, but the reasons are not well understood. In this project the investigators evaluated whether an increase in blood ammonia in patients with cirrhosis had an impact on sleep quality and the function of retinal ganglion cells measured by pupillary response to blue light.